Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q2 2024 · 10-Q
Revenue—
Net Income-$3.93M-$3.93MN/M vs Q2 2023 EPS Diluted-$34.00-$34.00N/M vs Q2 2023 Operating Income-$8,503,848N/M Operating Cash Flowderived-$10,928,704N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end